An Overview of High-Efficacy Drugs for Multiple Sclerosis: Gulf Region Expert Opinion

Raed Alroughani*, Jihad Said Inshasi, Dirk Deleu, Jasem Al-Hashel, Mustafa Shakra, Osama Robin Elalamy, Ahmed Osman Shatila, Abdullah Al-Asmi, Isa Al Sharoqi, Beatriz Garcia Canibano, Amir Boshra

*Corresponding author for this work

Research output: Contribution to journalComment/debatepeer-review

23 Citations (Scopus)


This article discusses the opinions of the multiple sclerosis (MS) experts in the Gulf region on the use of high-efficacy disease-modifying drugs (DMDs; natalizumab, fingolimod, alemtuzumab, cladribine tablets, and ocrelizumab) in clinical practice. The experts reviewed the current literature including pivotal clinical trials and meta-analyses for high-efficacy DMDs, supplemented by the expert opinions on the usage of these DMDs in clinical practice. Several criteria were discussed by the panel based on different efficacy, safety, and convenience attributes. The panel concluded that all the DMDs available for the treatment of MS have benefits and risks, which should be considered while discussing the treatment plan with the patient. It is important to have a personalized approach based on the risk-benefit assessment for each case. Common considerations while choosing treatments include effectiveness, side effects/safety, and convenience/route of administration. Funding: Merck Serono Middle East FZ LTD.

Original languageEnglish
Pages (from-to)13-23
Number of pages11
JournalNeurology and Therapy
Issue number1
Publication statusPublished - Jun 1 2019
Externally publishedYes


  • Disease-modifying drugs
  • Expert opinion
  • Gulf region
  • Multiple sclerosis
  • Neuroimmunology

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology


Dive into the research topics of 'An Overview of High-Efficacy Drugs for Multiple Sclerosis: Gulf Region Expert Opinion'. Together they form a unique fingerprint.

Cite this